We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-7.7%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$211M
AUM Growth
+$27.6M
Cap. Flow
+$53.8M
Cap. Flow %
25.48%
Top 10 Hldgs %
55.57%
Holding
55
New
15
Increased
12
Reduced
13
Closed
14

Top Buys

Rank Stock Value
1
CNC icon
Centene
CNC
+$11.5M
2
ADCT icon
ADC Therapeutics
ADCT
+$10.3M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$9.22M
4
KZR
Kezar Life Sciences
KZR
+$8.36M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$8.32M

Top Sells

Rank Stock Value
1
ALBO
Albireo Pharma Inc
ALBO
+$10.5M
2
TNET icon
TriNet
TNET
+$5.29M
3
HCAT icon
Health Catalyst
HCAT
+$3.7M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$3.68M
5
ALDX icon
Aldeyra Therapeutics
ALDX
+$3.36M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNYA icon
51
Tenaya Therapeutics
TNYA
$168M
– –
-107,063
Closed -$215K
SGEN
52
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-12,000
Closed -$1.54M
OSH
53
DELISTED
Oak Street Health, Inc.
OSH
– –
-84,000
Closed -$1.81M
CSII
54
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-145,916
Closed -$1.99M
ALBO
55
DELISTED
Albireo Pharma Inc
ALBO
– –
-486,726
Closed -$10.5M
1 2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q1 2023 Portfolio in Review

As of Q1 2023, Prosight Management held 55 positions worth $211M, up 15% from $183M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Prosight Management deployed $53.8M of net new capital in Q1 2023, opening 15 new positions and adding to 12 existing holdings. Its largest new stake was Centene: 161,404 shares worth $10.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Lakefront Biotherapeutics American Depositary Shares, an estimated $3.68M trimmed.

  • Prosight Management's largest Q1 2023 buy was Centene: 161,404 shares worth $10.2M.
  • Prosight Management added most to ADC Therapeutics in Q1 2023, an estimated $10.3M increase.
  • Prosight Management's biggest Q1 2023 reduction was Lakefront Biotherapeutics American Depositary Shares, cutting an estimated $3.68M.
  • Prosight Management fully exited Albireo Pharma Inc in Q1 2023, selling an estimated $10.5M.
  • Prosight Management's ten largest holdings make up 56% of its $211M portfolio in Q1 2023.
  • Prosight Management opened 15 new positions and closed 14 in Q1 2023.
  • Prosight Management's portfolio value rose 15% quarter-over-quarter to $211M.

Based on Prosight Management's 13F filing for Q1 2023, filed 12 May 2023.